| Dr Ranjan Chowdhry, MD | |
|
1003 S Main St, Bellingham, MA 02019-1826 | |
| (508) 883-0600 | |
| (508) 883-5990 |
| Full Name | Dr Ranjan Chowdhry |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 28 Years |
| Location | 1003 S Main St, Bellingham, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386794675 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 230814 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vna And Hospice Of Greater Milford | Milford, MA | Home health agency |
| Preferred Transitions Home Health Care Inc | Milford, MA | Home health agency |
| Vna Care Network | Worcester, MA | Home health agency |
| Milford Regional Medical Center | Milford, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Milford Regional Physician Group, Inc. | 5597679449 | 233 |
News Archive
More than a decade before people with Huntington's disease show symptoms, they can exhibit abnormally high levels of an immune-system molecule called interleukin-6 (IL-6), which has led many researchers to suspect IL-6 of promoting the eventual neurological devastation associated with the genetic condition.
Led by Claudio Soto, Ph.D., researchers from McGovern Medical School at The University of Texas Health Science Center at Houston have been awarded $11 million from the National Institute of Allergy and Infectious Diseases to study the pathogenesis, transmission and detection of prion diseases - such as chronic wasting disease in deer - that can potentially spread to humans.
Determining whether or not an individual has dementia and to what degree is a long and laborious process that can take an experienced professional such as a clinician about four to five hours to administer, interpret and score the test results. A leading neuroscientist at Florida Atlantic University has developed a way for a layperson to do this in three to five minutes with results that are comparable to the "gold standard" dementia tests used by clinicians today.
Delcath Systems, Inc. a development stage, specialty pharmaceutical and medical device company focused on oncology, highlighted the Phase III trial data presented on June 5 at the American Society of Clinical Oncology's 2010 Annual Meeting, comparing percutaneous hepatic perfusion with melphalan to the best alternative care for patients with hepatic metastases from ocular or cutaneous melanoma.
› Verified 4 days ago
| Entity Name | Milford Regional Physician Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902856024 PECOS PAC ID: 5597679449 Enrollment ID: O20040503001341 |
News Archive
More than a decade before people with Huntington's disease show symptoms, they can exhibit abnormally high levels of an immune-system molecule called interleukin-6 (IL-6), which has led many researchers to suspect IL-6 of promoting the eventual neurological devastation associated with the genetic condition.
Led by Claudio Soto, Ph.D., researchers from McGovern Medical School at The University of Texas Health Science Center at Houston have been awarded $11 million from the National Institute of Allergy and Infectious Diseases to study the pathogenesis, transmission and detection of prion diseases - such as chronic wasting disease in deer - that can potentially spread to humans.
Determining whether or not an individual has dementia and to what degree is a long and laborious process that can take an experienced professional such as a clinician about four to five hours to administer, interpret and score the test results. A leading neuroscientist at Florida Atlantic University has developed a way for a layperson to do this in three to five minutes with results that are comparable to the "gold standard" dementia tests used by clinicians today.
Delcath Systems, Inc. a development stage, specialty pharmaceutical and medical device company focused on oncology, highlighted the Phase III trial data presented on June 5 at the American Society of Clinical Oncology's 2010 Annual Meeting, comparing percutaneous hepatic perfusion with melphalan to the best alternative care for patients with hepatic metastases from ocular or cutaneous melanoma.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ranjan Chowdhry, MD 1003 S Main St, Bellingham Medical Associates, Bellingham, MA 02019-1826 Ph: (508) 883-0600 | Dr Ranjan Chowdhry, MD 1003 S Main St, Bellingham, MA 02019-1826 Ph: (508) 883-0600 |
News Archive
More than a decade before people with Huntington's disease show symptoms, they can exhibit abnormally high levels of an immune-system molecule called interleukin-6 (IL-6), which has led many researchers to suspect IL-6 of promoting the eventual neurological devastation associated with the genetic condition.
Led by Claudio Soto, Ph.D., researchers from McGovern Medical School at The University of Texas Health Science Center at Houston have been awarded $11 million from the National Institute of Allergy and Infectious Diseases to study the pathogenesis, transmission and detection of prion diseases - such as chronic wasting disease in deer - that can potentially spread to humans.
Determining whether or not an individual has dementia and to what degree is a long and laborious process that can take an experienced professional such as a clinician about four to five hours to administer, interpret and score the test results. A leading neuroscientist at Florida Atlantic University has developed a way for a layperson to do this in three to five minutes with results that are comparable to the "gold standard" dementia tests used by clinicians today.
Delcath Systems, Inc. a development stage, specialty pharmaceutical and medical device company focused on oncology, highlighted the Phase III trial data presented on June 5 at the American Society of Clinical Oncology's 2010 Annual Meeting, comparing percutaneous hepatic perfusion with melphalan to the best alternative care for patients with hepatic metastases from ocular or cutaneous melanoma.
› Verified 4 days ago
Bradley E Harris, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 1003 S Main St, Bellingham, MA 02019 Phone: 508-883-0600 Fax: 508-883-5990 | |
Michael Charles Pescatello, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 1003 S Main St, Bellingham, MA 02019 Phone: 508-883-0600 Fax: 508-883-5990 | |
Irina Pieleanu, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1003 S Main St, Bellingham, MA 02019 Phone: 508-883-0600 Fax: 508-883-5990 | |
Mengtao Zhang, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1003 S Main St, Bellingham, MA 02019 Phone: 088-830-6005 Fax: 508-883-5990 | |
Pradeep Kumar, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1003 S Main St, Bellingham, MA 02019 Phone: 508-883-0600 Fax: 508-883-5990 | |
Ann E Rickert, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1003 S Main St, Bellingham, MA 02019 Phone: 508-883-0600 Fax: 508-883-5990 |